Advertisement

Tumor Biology

, Volume 37, Issue 12, pp 15883–15891 | Cite as

IL-17A produced by peritoneal macrophages promote the accumulation and function of granulocytic myeloid-derived suppressor cells in the development of colitis-associated cancer

  • Yue Zhang
  • Juan Wang
  • Wenxin Wang
  • Jie Tian
  • Kai Yin
  • Xinyi Tang
  • Jie Ma
  • Huaxi Xu
  • Shengjun Wang
Original Article
  • 422 Downloads

Abstract

It is widely acknowledged that a close relationship is between inflammation and colon cancer. Interleukin (IL)-17A and myeloid-derived suppressor cells (MDSCs) play an important role in the development of colitis-associated cancer (CAC). However, the precise changes of IL-17, MDSCs, and Th17 cells during the CAC progression have not been observed in the colorectal chronic inflammation-dependent tumor. In this study, we found the level of IL-17 was increased in pathogenic colon site during the early stage of CAC model. Further experiments showed the increased IL-17 was probably secreted by peritoneal macrophages when exposed to dextran sulfate sodium (DSS). In vitro, we found that IL-17 could enhance survival and suppressive function of granulocytic (G)-MDSCs, the subset associated with inflammation. With the development of CAC, the proportions of MDSCs and Th17 cells were continuously increased by the high level of IL-17 produced by macrophages. However, the increase of MDSCs was earlier and acuter than that of Th17 cells. Selective depletion of MDSCs not only slowed down CAC process but also significantly reduce Th17 cells in vivo. Thereafter, we demonstrated that in the development of CAC, IL-17 secreted by peritoneal macrophages could promote the accumulation of G-MDSCs, then the proportion of Th17 cells was increased, and finally promote the development of CAC.

Keywords

IL-17  Th17 cells Granulocytic myeloid-derived suppressor cells Colitis-associated cancer 

Notes

Acknowledgments

This work was supported by the Specialized Project for Clinical Medicine of Jiangsu Province (Grant No. BL2014065), Natural Science Foundation of Jiangsu (Grant No. BK20150533), National Natural Science Foundation of China (Grant No. 31170849, 31470881, 81601424), Project funded by China Postdoctoral Science Foundation (Grant No. 2016M590423), Science and Technology Support Program (Social Development) of Zhenjiang (Grant No. SH2014039), Jiangsu Province “333” Project (Grant No. BRA2015197), Summit of the Six Top Talents Program of Jiangsu Province (Grant No. 2015-WSN-116), Jiangsu University Science Foundation (Grant Nos. 11JDG093, FCJJ2015022, 15JDG070), Jiangsu Key Laboratory of Laboratory Medicine Foundation (Grant No. JSKLM-2014-013), Medical Science and Technology Foundation of Jiangsu University (Grant No. JLY20140004), and Priority Academic Program Development of Jiangsu Higher Education Institutions.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1090–100.CrossRefPubMedGoogle Scholar
  2. 2.
    Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–89.CrossRefPubMedGoogle Scholar
  3. 3.
    Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003;124:762–77.CrossRefPubMedGoogle Scholar
  4. 4.
    Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119:3011–23.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen J, Tian J, Tang X, et al. MiR-346 regulates CD4 + CXCR5 + T cells in the pathogenesis of Graves disease. Endocrine. 2015;49:752–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Chien YH, Zeng X, Prinz I. The natural and the inducible: interleukin (IL)-17-producing gammadelta T cells. Trends Immunol. 2013;34:151–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.CrossRefPubMedGoogle Scholar
  9. 9.
    He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184:2281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114:596–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hyun YS, Han DS, Lee AR, et al. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 2012;33:931–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis. 2015;21:623–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Kondo T, Takata H, Matsuki F, et al. Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol. 2009;182:1794–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–47.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Le HK, Graham L, Cha E, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9:900–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Ma S, Cheng Q, Cai Y, et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 2014;74:1969–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.CrossRefPubMedGoogle Scholar
  20. 20.
    Miyahara Y, Odunsi K, Chen W, et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:15505–10.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Monteiro M, Almeida CF, Agua-Doce A, et al. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-beta and IL-1beta. J Immunol. 2013;190:805–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin Immunol. 2015;27:249–56.CrossRefPubMedGoogle Scholar
  24. 24.
    Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16:53–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Tian J, Ma J, Ma K, et al. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol. 2013;43:1220–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Tian J, Rui K, Tang X, et al. MicroRNA-9 regulates the differentiation and function of myeloid-derived suppressor cells via targeting Runx1. J Immunol. 2015;195:1301–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Vincent J, Mignot G, Chalmin F, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wang S, Shi Y, Yang M, et al. Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells. Am J Pathol. 2012;180:1059–67.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang S et al. Cell-derived leptin contributes to increased frequency of Th17 cells in female patients with Hashimoto’s thyroiditis. Clin Exp Immunol. 2013;171:63–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang Y, Tian J, Wang S. The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis. Semin Arthritis Rheum. 2016;45:490–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Watanabe T, Konishi T, Kishimoto J, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17:802–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Wu C, Wang S, Wang F, et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 2009;158:199–204.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Wu P, Wu D, Ni C, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40:785–800.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–55.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–8.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Yue Zhang
    • 1
  • Juan Wang
    • 2
  • Wenxin Wang
    • 2
  • Jie Tian
    • 2
  • Kai Yin
    • 3
  • Xinyi Tang
    • 1
  • Jie Ma
    • 2
  • Huaxi Xu
    • 2
  • Shengjun Wang
    • 1
    • 2
  1. 1.Department of Laboratory Medicine, The Affiliated People’s HospitalJiangsu UniversityZhenjiangChina
  2. 2.Institute of Laboratory Medicine, Jiangsu Key Laboratory of Laboratory MedicineJiangsu UniversityZhenjiangChina
  3. 3.Department of General Surgery, The Affiliated HospitalJiangsu UniversityZhenjiangChina

Personalised recommendations